Skip to content

Insulin Lispro Protamine/Insulin Lispro

    Brands

    DEA Class; Rx

    Common Brand Names; Humalog Mix 50/50, Humalog Mix 50/50 Kwikpen, Humalog Mix 75/25, Humalog Mix 75/25 Kwikpen

    • Antidiabetics, Insulins

    A combination of insulin lispro and insulin lispro protamine; fixed-ratio mixtures
    Used for type 1 and type 2 diabetes mellitus
    For type 2 diabetes, most commonly given twice daily

    Indicated for the treatment of type 1 diabetes mellitus.

    For the treatment of type 2 diabetes mellitus.

    Hypersensitivity

    During episodes of hypoglycemia

    Hypoglycemia

    Insulin resistance

    Lipodystrophy

    Lipohypertrophy

    Local allergic reaction

    Hypokalemia

    Injection site reactions

    Weight gain

    Edema

    Pruritus

    Rash

    Never share pen between patients even it needle is changed

    Suspension for SC use, do not administer IV

    Administer within 15 minutes of meals (rapid onset and peak ~1 hr)

    Rapid changes in serum glucose may induce symptoms of hypoglycemia

    Early warning symptoms of hypoglycemia may be different or less pronounced under certain conditions (eg, long duration of diabetes, diabetic nerve disease, use of beta-blockers or intensified diabetes control)

    Caution in conditions with decreased insulin requirements (eg, diarrhea, nausea, vomiting, malabsorption, hypothyroidism, renal impairment, hepatic impairment)

    Caution in conditions with increased insulin requirements (eg, fever, hyperthyroidism, trauma, infection, surgery)

    Thiazolidinediones are peroxisome proliferator-activated receptor (PPAR)-gamma agonists and can cause dose-related fluid retention, particularly when used in combination with insulin; fluid retention may lead to or exacerbate heart failure, monitor for signs and symptoms of heart failure and treat accordingly and consider discontinuing thiazolidinediones

    Glucose monitoring recommended for all patients with diabetes

    Do not mix with other insulins

    Do not administer via insulin infusion pump

    Hypoglycemia may be life-threatening; increase frequency of blood glucose monitoring with changes to insulin dosage, co-administered glucose lowering medications, meal pattern, physical activity; in patients with renal or hepatic impairment; and in patients with hypoglycemia unawareness

    Accidental mix-ups between insulin products can occur; instruct patients to check insulin labels before injection

    Severe, life-threatening, generalized allergy, including anaphylaxis, reported; discontinue therapy, monitor, and treat if indicated

    Hypokalemia may occur; may be life-threatening; monitor potassium levels in patients at risk of hypokalemia and treat if indicated

    The limited available data in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes

    There are no data on presence of drug in human milk, effects on breastfed infant, or on milk production

    Specific maximum dosage information is not available. Individualize dosage based on careful monitoring of blood glucose and other clinical parameters in all patient populations.

    insulin lispro protamine rDNA origin/insulin lispro rDNA origin

    insulin lispro protamine/insulin lispro

    subcutaneous injection

    • (75units/25units)/mL
    • (50units/50units)/mL